US FDA has granted its approval to Wockhardt Ltd for marketing a generic version of 2mg, 4mg, 6mg, 8mg (and) 12mg extended-release tablets containing Ropinirole hydrochloride, used in the treatment of Parkinson's disease. Ropinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. Wockhardt has announced that it will launch the product very soon. According to IMS Health, the total market for this product ...Tuesday, 28 August 2012
US FDA Approves Generic Version of Wockhardt's Drug to Treat Parkinson's Disease
US FDA has granted its approval to Wockhardt Ltd for marketing a generic version of 2mg, 4mg, 6mg, 8mg (and) 12mg extended-release tablets containing Ropinirole hydrochloride, used in the treatment of Parkinson's disease. Ropinirole extended release tablet is the generic name for the brand Requip XL, marketed in the US by Glaxo SmithKline. Wockhardt has announced that it will launch the product very soon. According to IMS Health, the total market for this product ...
Labels:
Health News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment